Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBER trial of patiromer to enable spironolactone use in resistant hypertension with chronic kidney disease
2016-002657-38Phase 2Completed
- Sponsor
- Relypsa, Inc.
- Start
- Nov 2016
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in resistant hypertension (RH) and chronic kidney disease (CKD) comparing Spironolactone + patiromer with Spironolactone + placebo (2 arms). Primary endpoint: Proportion remaining on spironolactone at Week 12. Started Nov 2016; status: completed.
02
Drugs
patiromer
03
Conditions
resistant hypertension (RH)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2016-002657-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002657-38.